Baseline demographic and disease characteristics of progressors and nonprogressors. Progressors were defined as patients with a change from baseline in total van der Heijde-Sharp (vdH-S) score > 0.5 at Week 28.
| Characteristic | Placebo + MTX | Combined Golimumab ± MTX | ||
|---|---|---|---|---|
| No Progression | Progression | No Progression | Progression | |
| Patients, n | 23 | 14 | 91 | 24 |
| Age, yrs | ||||
| Mean (SD) | 49.4 (12.0) | 46.1 (11.0) | 47.1 (12.5) | 50.0 (12.9) |
| Median (IQR) | 52.0 (40.0, 57.0) | 46.0 (37.0, 58.0) | 48.0 (38.0, 54.0) | 49.0 (40.5, 59.0) |
| Female, n (%) | 20 (87.0) | 12 (85.7) | 74 (81.3) | 21 (87.5) |
| Race, n (%) | ||||
| Asian | 4 (17.4) | 2 (14.3) | 16 (17.6) | 4 (16.7) |
| Black | 0 (0.0) | 1 (7.1) | 0 (0.0) | 0 (0.0) |
| White | 19 (82.6) | 7 (50.0) | 68 (74.7) | 15 (62.5) |
| Other | 0 (0.0) | 4 (28.6) | 7 (7.7) | 5 (20.8) |
| CRP, mg/dl | ||||
| Mean (SD) | 1.8 (2.1) | 3.6 (2.9)* | 1.9 (2.0) | 2.7 (3.1) |
| Median (IQR) | 1.1 (0.4, 1.8) | 2.7 (0.9, 4.4) | 1.2 (0.5, 2.4) | 1.8 (0.5, 3.6) |
| Disease duration, yrs | ||||
| Mean (SD) | 1.9 (1.7) | 3.2 (5.9) | 3.2 (4.9) | 5.9 (10.8) |
| Median (IQR) | 1.2 (0.5, 3.2) | 1.4 (0.6, 2.7) | 1.1 (0.6, 3.3) | 1.8 (0.9, 5.8) |
| vdH-S score (0–448) | ||||
| Mean (SD) | 8.1 (16.1) | 20.0 (45.4) | 16.6 (34.2) | 32.7 (65.6) |
| Median (IQR) | 3.0 (1.5, 6.0) | 6.0 (3.0, 12.0) | 4.1 (2.0, 12.5) | 9.8 (3.5, 41.8) |
↵* p < 0.05. CRP: C-reactive protein; IQR: interquartile range; MTX: methotrexate.